Episode Details

Back to Episodes
Programmable RNA 2.0: Beyond the First mRNA Revolution

Programmable RNA 2.0: Beyond the First mRNA Revolution

Published 5 months ago
Description

In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklud, CEO of Circio and Jacob Becraft, CO-founder and CEO of Strand Therapeutics.

Since the mRNA vaccine breakthroughs of the COVID-19 era, attention has turned to what's next for programmable medicines. While first- generation mRNA prove the power of transient genetic instruction, its instability, immune reactivity, and short-lived expression have limited its use mainly to vaccines. Emerging platforms like circular and logic circuit RNA are expanding the field's therapeutic horizons.

Host

Jennifer Smith-Parker, Director of Insights, BioSpace

Guests

Erik Digman Wiklund⁠, CEO, Circio

Jacob Becraft, Co-founder and CEO, Strand Therapeutics


Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us